이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MediPharm Labs 관리

관리 기준 확인 3/4

MediPharm Labs' CEO는 David Pidduck, Apr2022 에 임명되었습니다 의 임기는 2.17 년입니다. 총 연간 보상은 CA$ 1.31M, 36% 로 구성됩니다. 36% 급여 및 64% 보너스(회사 주식 및 옵션 포함). 는 CA$ 934.32K 가치에 해당하는 회사 주식의 3.3% 직접 소유합니다. 934.32K. 경영진과 이사회의 평균 재임 기간은 각각 4.7 년과 5 년입니다.

주요 정보

David Pidduck

최고 경영자

CA$1.3m

총 보상

CEO 급여 비율	36.0%
CEO 임기	2.2yrs
CEO 소유권	3.3%
경영진 평균 재임 기간	4.7yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11

CEO 보상 분석

David Pidduck 의 보수는 MediPharm Labs 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$19m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

보상 대 시장: David 의 총 보상 ($USD 951.96K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Pidduck

2.2yrs

테뉴어

CA$1,305,051

보상

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Pidduck	CEO & Director	2.2yrs	CA$1.31m	3.3% CA$ 934.3k
Keith Strachan	Co-Founder & President	5.3yrs	CA$819.48k	0.51% CA$ 143.5k
Greg Hunter	Chief Financial Officer	3.3yrs	CA$957.75k	0.21% CA$ 59.7k
Patrick McCutcheon	Founder	9.4yrs	CA$858.16k	데이터 없음
Brett Moon	Vice President of Sales	4.1yrs	데이터 없음	데이터 없음
Kirk Binns	Executive Vice President of Global Accounts	5.3yrs	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

경험이 풍부한 관리: LABS 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Pidduck	CEO & Director	2.2yrs	CA$1.31m	3.3% CA$ 934.3k
Shelley Martin	Independent Director	4yrs	CA$64.49k	데이터 없음
Michael Bumby	Independent Director	1.2yrs	CA$34.45k	0.029% CA$ 8.1k
Christopher Taves	Independent Chairman of the Board	3.9yrs	CA$87.14k	0.25% CA$ 70.0k
Miriam McDonald	Member of the Science Advisory Board	5.2yrs	CA$32.40k	데이터 없음
Leslie Brown	Member of the Science Advisory Board	5.2yrs	데이터 없음	데이터 없음
Matt Archibald	Member of the Science Advisory Board	5.2yrs	데이터 없음	데이터 없음
Markus Roggen	Member of the Science Advisory Board	5.2yrs	데이터 없음	데이터 없음
Arshad Hack	Member of the Science Advisory Board	5.2yrs	데이터 없음	데이터 없음
Jerry King	Member of the Science Advisory Board	5.2yrs	데이터 없음	데이터 없음
Carolina Landolt-Marticorena	Member of the Science Advisory Board	4.8yrs	데이터 없음	데이터 없음
Christopher Halyk	Independent Director	3.8yrs	CA$56.05k	0.021% CA$ 6.0k

5.0yrs

평균 재임 기간

경험이 풍부한 이사회: LABS 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

MediPharm Labs 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

CEO & Director exercised options to buy CA$130k worth of stock.

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

High number of new and inexperienced directors

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Recent updates

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

MediPharm Labs (TSE:LABS) Is Using Debt Safely

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

Consensus estimates of losses per share improve by 25%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

New minor risk - Share price stability

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 11%

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

CEO & Director exercised options to buy CA$130k worth of stock.

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Consensus revenue estimates increase by 47%, EPS downgraded

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Consensus revenue estimates fall by 20%

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to CA$0.25

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Consensus revenue estimates fall by 13%

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold CA$87k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to CA$0.65

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold CA$483k worth of stock